SURVYR

MDLN

Medline Inc.
$32.37
−$0.01 (0.03%)Oct 28 close
Healthcare CompareTechnicals
Model valuationLeans expensiveDCF base $22
1M3M6M1Y2Y
-23%-11%0%+12%+24%Dec 2025Oct 2026May 202652w high $50.8852w low $31.49
MDLNSPY
Wall St. Highest PT $55.00 (+69.9%) Wall St. Avg PT $44.31 (+36.9%)
$32$42$53$63$74POC $36Hi $55Avg $44
Underwater Drawdown %Max DD -36.7%Current -35.2%
0.0%-36.7%
Relative Strength vs SPY-37.3% vs SPYUnderperforming
+44%0%-44%
1W
−$2.94 (8.33%)
1M
−$2.70 (7.70%)
3M
−$7.71 (19.24%)
6M
−$11.03 (25.41%)
YTD
−$9.63 (22.93%)
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
26 analysts · mean score 1.56
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$32.37
Average target$44.31
+$11.94 (+36.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$34.00
Median$45.00
High$55.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Grey zone
Altman Z-score 2.5
Above 2.99 is the safe zone, below 1.81 the distress zone.

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 27, 2026). Descriptive, not a forecast.

Key stats & company

Market value$43.6B
P/E (last 12 months)83.0
P/E (next 12 months, estimated)20.6
52-week range$31.49 – $50.88
Revenue growth (latest quarter vs a year ago)+11.6%
Dividend yieldNo dividend
Analyst consensusBuy (26)
Average analyst price target$44.31 (+37%)

What they do

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics.

Healthcare · Medical Instruments & Supplies
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -1 (DCF counts double).
▼DCF (base case)below the price by 33%
•Altman Z2.5 (grey)
•Net debt / EBITDA3.5x
▲Analyst target+37% (26 analysts)

Discounted cash flow

Bear
$11
-66%
growth 7% · disc. 10.2% · term. 2.0%
Base
$22
-33%
growth 12% · disc. 9.2% · term. 2.5%
Bull
$36
+12%
growth 15% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows about 13% a year for 10 years.
Implied
+13%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
n/a
Revenue, last 5 yrs
n/a
Same inputs as the DCF above: trailing free cash flow 1.5B, 9.2% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-27). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $1.57 vs trailing $0.39 (+302% expected growth). Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
26.2%
Operating margin
6.1%
FCF margin
5.2%
Net margin
3.9%
Return on equity
10.0%
Return on invested capital
6.9%
Net debt / EBITDA
3.5×
Current ratio
4.3×
Interest cover
2.3×
Cash conversion (OCF/NI)
1.7×

Altman Z-score 2.5 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$44
+37%
Analysts
26
Buy
Range
$34–$55
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$28.4B$1.2B$1.3B
2024$25.5B–$1.4B
2023$23.2B–$1.4B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

For information only · Important disclosures

Grades vs sector

No sector grades for MDLN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

MDLN earningsNext report in 6 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Before the open
EPS consensus$0.35
Revenue consensus–
Last 3 quarters · EPS vs estimate
Aug 5, 2026$0.50est $0.32+55.8%Above estimates
May 6, 2026$0.33est $0.29+12.2%Above estimates
Feb 25, 2026$0.31est $0.24+30.0%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:04:55 ET
26-0226-0526-080.000.50
EstimateActual (beat)Actual (miss)

News & catalysts

More news
What Capital Group Core Equity ETF (CGUS) Bought: Medline Leads on Thursday
GuruFocus.com · Oct 19
Insider trades
Gic Private Ltd
10% owner · 2026-10-08
Sell
$274.8M
Gic Private Ltd
10% owner · 2026-10-06
Sell
$251.8M
Gic Private Ltd
10% owner · 2026-10-06
Sell
$73.2M
Gic Private Ltd
10% owner · 2026-10-05
Sell
$60.4M
Gic Private Ltd
10% owner · 2026-10-02
Sell
$245.4M
Gic Private Ltd
10% owner · 2026-10-02
Sell
$90.9M
Gic Private Ltd
10% owner · 2026-08-14
Sell
$3.6M
Gic Private Ltd
10% owner · 2026-08-13
Sell
$53.7M
Gic Private Ltd
10% owner · 2026-08-07
Sell
$21.0M
Gic Private Ltd
10% owner · 2026-08-06
Sell
$9.6M
Gic Private Ltd
10% owner · 2026-08-05
Sell
$9.7M
Gic Private Ltd
10% owner · 2026-08-05
Sell
$60.7M

Stats refreshed 2026-10-27 18:04:55 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026